Keryx Biopharmaceuticals Inc (KERX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Keryx Biopharmaceuticals Inc (KERX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10074
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company’s lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based phosphate binder, which helps lower the amount of phosphate in human blood. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric (ferric citrate coordination complex). The company has subsidiaries and offices in Israel, the US, and the UK. Keryx is headquartered in New York City, New York, the US.

Keryx Biopharmaceuticals Inc (KERX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Merger 11
Akebia Therapeutics and Keryx Biopharma to Merge 11
Equity Offering 13
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 13
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 14
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 16
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 18
Debt Offering 20
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 20
Acquisition 21
Baupost Acquires 10.7% Stake In Keryx Biopharma 21
Keryx Biopharmaceuticals Inc – Key Competitors 22
Keryx Biopharmaceuticals Inc – Key Employees 23
Keryx Biopharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 08, 2018: Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results 25
May 10, 2018: Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results 26
Feb 07, 2018: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 27
Nov 07, 2017: Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results 29
Jul 27, 2017: Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance 30
May 04, 2017: Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results 32
Mar 01, 2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results 34
Corporate Communications 36
Apr 30, 2018: Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue 36
Sep 13, 2017: Keryx Biopharmaceuticals Announces Changes to its Board of Directors 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keryx Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Akebia Therapeutics and Keryx Biopharma to Merge 11
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 13
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 14
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 16
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 18
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 20
Baupost Acquires 10.7% Stake In Keryx Biopharma 21
Keryx Biopharmaceuticals Inc, Key Competitors 22
Keryx Biopharmaceuticals Inc, Key Employees 23
Keryx Biopharmaceuticals Inc, Subsidiaries 24

List of Figures
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Keryx Biopharmaceuticals Inc (KERX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lloyds Banking Group Plc:戦略・SWOT・企業財務分析
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • NicOx SA (COX)-医療機器分野:企業M&A・提携分析
    Summary NicOx SA (NicOx) is an pharmaceutical company that develops ophthalmic portfolio of therapies and diagnostic tools. The company offers ophthalmic products which include AdenoPlus, AzaSite, BromSite, Xailin, Vesneo, next generation NO-donors and Syk and JAK inhibitors, and others. It offers p …
  • The Toro Company:企業の戦略・SWOT・財務情報
    The Toro Company - Strategy, SWOT and Corporate Finance Report Summary The Toro Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sunningdale Tech Ltd (BHQ):企業の財務・戦略的SWOT分析
    Summary Sunningdale Tech Ltd (Sunningdale) is a chemical company that manufactures and markets tooling and plastic injection moulding components. The company's plastic solutions include product and mould designs, injection moulding, mould fabrication, complementary finishings, and precision assembly …
  • Audentes Therapeutics Inc (BOLD):企業の財務・戦略的SWOT分析
    Summary Audentes Therapeutics Inc (Audentes) is a biotechnology company. It focuses on the development and commercialization of gene therapy products for rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment …
  • Nitto Denko Corporation:企業の戦略・SWOT・財務分析
    Nitto Denko Corporation - Strategy, SWOT and Corporate Finance Report Summary Nitto Denko Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • El Paso Electric Company:企業の発電所・SWOT分析2018
    El Paso Electric Company - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • C.A. Curtze Co. Inc.:企業の戦略・SWOT・財務分析
    C.A. Curtze Co. Inc. - Strategy, SWOT and Corporate Finance Report Summary C.A. Curtze Co. Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • MGM China Holdings Ltd:戦略・SWOT・企業財務分析
    MGM China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary MGM China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Martifer SGPS SA (MAR):企業の財務・戦略的SWOT分析
    Martifer SGPS SA (MAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Methanex Corp (MX):企業の財務・戦略的SWOT分析
    Methanex Corp (MX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of n …
  • Oil and Natural Gas Corporation Ltd (ONGC)-エネルギー分野:企業M&A・提携分析
    Summary Oil and Natural Gas Corporation Ltd (ONGC) is an integrated oil and gas company. It explores for and produces oil and natural gas; refines crude oil; and markets and distributes petroleum products. The company's product portfolio includes crude oil, natural gas, liquefied natural gas, naphth …
  • CRRC Corporation Limited:企業の戦略・SWOT・財務情報
    CRRC Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary CRRC Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • TDK Corporation:戦略・SWOT・企業財務分析
    TDK Corporation - Strategy, SWOT and Corporate Finance Report Summary TDK Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tilaknagar Industries Ltd:企業の戦略・SWOT・財務分析
    Tilaknagar Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Tilaknagar Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • GenomeDx Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary GenomeDx Biosciences Inc (GenomeDx) is a genomic information company developing solutions for prostate cancer treatment and the management of other urologic cancers. The company offers decipher prostate cancer classifier, a transformative genomic test that provides an assessment of tumor agg …
  • Miromatrix Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Miromatrix Medical Inc (Miromatrix Medical) is a life science company that develops regenerative medicines. The company offers MIRODERM biologic wound matrix, MIROMESH biologic matrix, liver function restoration, kidney products, diabetes treatment and cortical strut. It creates biological r …
  • Onconova Therapeutics Inc (ONTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Onconova Therapeutics Inc (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib, briciclib and recilisib. It develops drug candidates that target cancer and protect he …
  • Borealis AG:企業の戦略的SWOT分析
    Borealis AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆